On this page
Palo Alto is better known for software, but health and life science money has been part of the local venture story from the start. Kleiner Perkins backed Genentech in the 1970s. Syntex spent half a century in Stanford Research Park. Today Stanford Medicine sits a short walk from University Avenue and a group of Sand Hill Road firms keeps dedicated health care teams.
This guide explains how biotech and health investing works, introduces investors near Palo Alto as they describe themselves and lays out the Stanford programs that turn research into companies. It is not a ranking and it is not investment advice. For the general mechanics of venture funds, see our venture capital guide.
Four kinds of health company
"Biotech" is a loose word. Investors split health care into segments with very different timelines.
| Segment | Typical path | What investors watch |
|---|---|---|
| Therapeutics (drugs) | Lab research, animal studies, then Phase 1 to 3 trials over many years | Biology, trial design and FDA milestones |
| Medical devices | Prototype, bench testing, FDA clearance or approval, then hospital sales | Regulatory pathway and reimbursement |
| Diagnostics | Assay development, clinical validation, lab certification, payer coverage | Accuracy data and insurance coverage |
| Digital health | Software built for patients, clinicians or insurers | Adoption, privacy rules and who pays |
Drug companies usually raise the most and wait the longest. A digital health startup can look much like a software company. Devices and diagnostics fall in between. Palo Alto's own Guardant Health, a blood test company on Hanover Street, is a local example of the diagnostics path.
How the rounds work
Life science rounds tend to be tied to evidence rather than revenue. A seed round may fund experiments to confirm a target. A Series A may carry a drug into animal studies or a device into its first human use. Later rounds pay for clinical trials. Some companies go public before they sell any product, which software investors would find strange.
Many health investors also build companies themselves. A firm may license a discovery from a university, recruit an experienced CEO and fund the company in stages. Founders who come from a lab should expect investors to ask about patents and licensing early. Stanford's technology licensing office handles those agreements; our page on Stanford-linked funds explains the university's equity policy.
Investors near Palo Alto
These firms either have Sand Hill Road or Palo Alto offices or describe a health focus from nearby. We list how each describes itself.
NEA
New Enterprise Associates has its headquarters at 2855 Sand Hill Road and invests in technology and health care from seed to IPO. Separate leaders run the two practices. Its portfolio page groups health companies under digital health and life sciences.
Vivo Capital
Vivo Capital describes itself as a health care investment firm headquartered in Palo Alto, founded in 1996, with offices in Asia. Its profile lists biotechnology, pharmaceuticals, medical devices and health care services, with investing across venture, growth equity and public markets.
Sofinnova Investments
Sofinnova Investments lists Menlo Park as its home and also has offices in Boston and New York. It calls itself a clinical-stage biopharmaceutical venture capital firm. Its site reports about $4.6 billion under management as of September 30, 2025. It is a fit for drug companies with a candidate near or in the clinic, not for early software.
Multi-sector firms with health teams
- Khosla Ventures lists health among its main areas alongside climate, AI and fintech.
- Felicis groups part of its investing under health and bio.
- DCVC Bio, set up by Palo Alto's DCVC in 2018, covers life sciences, agriculture and industrial biology.
- Mayfield lists human health as one of its practice areas.
- GV, Alphabet's venture arm, invests in technology and life sciences from seed to growth.
Many specialist biotech funds sit in San Francisco, South San Francisco or Boston rather than on the Peninsula. Founders in Palo Alto pitch them regularly.
Stanford's medical ecosystem
Stanford Medicine combines the School of Medicine, Stanford Health Care and Stanford Medicine Children's Health. Its research labs, clinics and hospitals sit at the north end of campus near Welch Road. Our history of Stanford Medicine covers how it grew from a San Francisco medical school into one of the largest research operations in the country.
SPARK
SPARK is a university and industry partnership aimed at proving out drug and diagnostic ideas. Professor Daria Mochly-Rosen founded it; most accounts date its start to 2006. Faculty, clinicians, postdocs and graduate students apply. A panel of faculty and industry advisors reviews proposals once a year. Selected SPARK Scholars get funding for an average of two years, weekly seminars with industry and academic experts and mentoring from several advisors in their field. Other universities have copied the model.
Stanford Biodesign
The Stanford Mussallem Center for Biodesign runs a roughly 10 month Innovation Fellowship for people who want to invent medical technology. Fellows start by watching clinical care to find unmet needs, then design devices to meet them. Biodesign says 58 companies have launched from technologies started there.
StartX Med
StartX launched StartX Med in 2012. IEEE Spectrum reported that its first six-month session chose 12 companies from 37 applications. Today its page describes a nonprofit lab co-op with wet and dry labs, cell culture space and shared equipment, a mentor network drawn from biotech, devices and health IT and a quarterly Med Showcase. StartX takes no equity and charges no program fees, though lab access is priced separately. Founders need a Stanford connection. Our accelerators guide covers StartX in more detail.
Lab space near Palo Alto
Lab space is often the first hard problem for a new biotech company. Page Mill Labs, a 77,300 square foot wet lab incubator at 950 Page Mill Road in Stanford Research Park, rents benches and shared equipment to life science startups. The StartX Med co-op offers another option for Stanford founders. Larger companies usually lease their own buildings in the research park, along East Bayshore Road or farther north in South San Francisco. Our Stanford Research Park guide explains how leases there work.
Lessons from local history
Palo Alto has seen the best and the worst of health startups. Syntex, the steroid maker that helped create the birth control pill, moved its headquarters to Palo Alto in 1959 and spent half a century in the research park. Genentech, backed by Kleiner Perkins, helped launch the modern biotech industry. Theranos, which promised blood tests from a finger prick, raised large sums before collapsing in fraud; our Theranos profile covers its Palo Alto years. The lesson investors took from Theranos is simple: in health care, independent validation of the science matters more than the pitch.
Tips for health founders
- Lead with data. Health investors read the data before they read the market slides.
- Know your regulatory path. Say whether you expect a 510(k), a De Novo request, a PMA or a drug application. Explain why.
- Sort out your license. If the technology came from Stanford or a hospital, have the license terms ready.
- Find the right partner. Many firms have separate health partners. Pitch the person who covers your segment.
- Budget for time. Plan for trials and approvals to take longer than you hope, then raise enough to reach a clear milestone.
Good to know
- Stanford programs such as SPARK and Biodesign have their own application cycles. Check their sites for current dates.
- Venture firm offices are private. Ask for introductions through mentors, advisors or your licensing office.
- This page is general information, not medical, legal or investment advice.
Frequently asked questions
Which venture firms near Palo Alto invest in biotech and health care?
NEA, headquartered at 2855 Sand Hill Road, invests in both technology and health care from seed to IPO. Vivo Capital describes itself as a health care investor based in Palo Alto. Sofinnova Investments lists Menlo Park and focuses on clinical-stage biopharma. Khosla Ventures, Felicis, DCVC Bio and GV also invest in health or life sciences.
What is Stanford SPARK?
SPARK is a Stanford program that helps faculty, clinicians, postdocs and graduate students move drug and diagnostic ideas toward the clinic. Scholars get funding for about two years, weekly seminars and advice from volunteer industry experts. It was founded by chemical and systems biology professor Daria Mochly-Rosen.
What is StartX Med?
StartX Med is the medical and biotech track of StartX, the nonprofit accelerator for Stanford founders. It launched in 2012 and today runs a nonprofit lab co-op with wet and dry lab space, a mentor network and a quarterly Med Showcase. Founders need a Stanford connection to join StartX.
How is biotech funding different from software funding?
Biotech companies often need years of lab work and clinical trials before they have a product to sell. Rounds tend to be larger and tied to scientific or regulatory milestones. Investors usually have scientific or medical training and many firms build companies in house around a licensed discovery.
Where are biotech labs near Palo Alto?
Stanford Research Park has lab buildings including Page Mill Labs, a wet lab incubator at 950 Page Mill Road. The largest biotech cluster in the region is in South San Francisco, about 25 miles north. Many Stanford spinouts start in shared lab space before moving to their own buildings.